NYSE: BDXBecton Dickinson & Co Stock
$228.71+0.71 (+0.31%)
Updated Mar 27, 2025
BDX Price
$228.71
Fair Value Price
N/A
Market Cap
$65.67B
52 Week Low
$218.75
52 Week High
$251.99
P/E
38.37x
P/B
2.61x
P/S
3.18x
PEG
0.92x
Dividend Yield
1.74%
Revenue
$20.64B
Earnings
$1.73B
Gross Margin
45.2%
Operating Margin
12.23%
Profit Margin
8.4%
Debt to Equity
1.17
Operating Cash Flow
$4B
Beta
0.42
Next Earnings
May 1, 2025
Ex-Dividend
Mar 10, 2025
Next Dividend
Mar 31, 2025
BDX Overview
Becton, Dickinson and Company manufactures and sells medical devices, instrument systems, and reagents. It also offers consulting and analytics-related services to hospitals, healthcare systems, and networks of healthcare providers. Further, it offers preanalytical solutions for sample management and immunology research. The company was founded in 1897 and is headquartered to Franklin Lakes, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BDX's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
BDX
Ranked#7 of 43
Ranked#7 of 43
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $49.98 | B | |
| $103.27 | B | |
| $6.06 | B |
Be the first to know about important BDX news, forecast changes, insider trades & much more!
BDX News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BDX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BDX ($228.71) is trading above its intrinsic value of $118.74, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BDX is poor value based on its earnings relative to its share price (38.37x), compared to the US market average (31.08x)
P/E vs Market Valuation
BDX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more BDX due diligence checks available for Premium users.
Valuation
BDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
38.37x
Industry
42.1x
Market
31.08x
BDX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BDX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
BDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.61x
Industry
3.8x
BDX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BDX price to earnings growth (PEG)
For valuing profitable companies with growth potential
BDX is good value based... subscribe to Premium to read more.
PEG Value Valuation
BDX's financial health
Profit margin
Revenue
$5.2B
Net Income
$303.0M
Profit Margin
5.9%
BDX's Earnings (EBIT) of $2.53B... subscribe to Premium to read more.
Interest Coverage Financials
BDX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$54.7B
Liabilities
$29.5B
Debt to equity
1.17
BDX's short-term assets ($8.66B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BDX's long-term liabilities ($21.80B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BDX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$693.0M
Investing
$204.0M
Financing
-$1.9B
BDX's operating cash flow ($3.65B)... subscribe to Premium to read more.
Debt Coverage Financials
BDX vs Medical Stocks
Becton Dickinson & Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.